Introduction {#sec1_1}
============

Postoperative optic opacification of modern hydrophilic acrylic intraocular lenses (IOL) has been a significant complication leading to IOL explantation since 1999 \[[@B1]\]. The opacification is probably caused by a deposit of calcium and phosphate salts; however, the exact mechanism is unknown \[[@B2], [@B3], [@B4], [@B5]\].

The four major designs involved are Hydroview (Bausch and Lomb, Rochester, N.Y., USA), Memorylens (Ciba Vision, Duluth, Ga., USA), SC60B-OUV (Medical Developmental Research, Clearwater, Fla., USA) and Aqua-Sense (Ophthalmic Innovations International, Ontario, Calif., USA) \[[@B5], [@B6]\]. Early discovery of IOL opacification is important. A wrong diagnosis may in fact prompt surgeons to perform unnecessary surgical procedures like YAG laser capsulotomy or vitrectomy.

This case report discusses late opacification of the Akreos Adapt AO IOL.

Materials and Methods {#sec1_2}
=====================

In 2008, a 79-year-old Italian man had had a phacoemulsification and hydrophilic acrylic IOL (Akreos Adapt AO, Bausch & Lomb) implantation in the right eye. The patient had been diagnosed with the pseudoexfoliation syndrome. He had had monocular vision because of an end-stage glaucoma in the left eye. Phacoemulsification had been performed through a clear corneal incision, and a dispersive ophthalmic viscosurgical device (Provisc^®^) was used. The patient had had a history of untreated hyperglycemia and hypertension. At that time, the ocular fundus showed no diabetic changes. Preoperatively, the best corrected visual acuity (BCVA) had been 0.4 in the right eye. Two weeks after surgery, the BCVA had improved to 0.9. Postoperative medication included bromfenac 0.9 mg/ml eyedrops (Yellox) and ofloxacin 0.3% eyedrops (Exocin), 1 drop 4 times daily for 4 weeks.

In 2011, an Ex-press device had been implanted in the right eye with mitomycin application. Later, he had had a choroidal detachment, for which he had undergone transcleral drainage. In September 2012, the patient complained of decreased visual acuity in the right eye (the BCVA was 0.3). There was significant IOL opacity localized to the anterior surface of the IOL. Complete blood count and the serum calcium level were within normal ranges. The IOL was explanted together with the capsular bag, and an iris-claw lens (Artisan Aphakia OPHTEC) was implanted.

Results {#sec1_3}
=======

The Akreos Adapt AO IOL showed widespread deposits that seem to be inside the optic (fig. [1](#F1){ref-type="fig"}, fig. [2](#F2){ref-type="fig"}). Scratching of the lens did not remove the deposits. Chemical and histopathological analysis was not carried out for the unavailability of the lens; however, the deposits were similar to another case described by Lee et al. \[[@B7]\] in 2010. After the operation, our patient had a BCVA of 0.6 in the right eye and no other complications.

Conclusion {#sec1_4}
==========

IOL opacification is a rare but possible event. The exact reason for the opacification is unknown. This alteration is most common in patients with diabetes or hypertension \[[@B8]\]. A case of an Akreos Adapt AO IOL opacification was described by Lee et al. \[[@B7]\] in a patient with diabetes and hypertension. Metabolic imbalance, altered fluid dynamics of the aqueous, or a breakdown of the blood-aqueous barrier in diabetic patients, combined with other factors, may be responsible for the opacification \[[@B8], [@B9]\]. In the present case, the deposits probably consisted of calcium-phosphorus aggregates as described in other diabetic or hyperglycemic patients.
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![Surgical exchange of an opacified Akreos Adapt AO IOL. **a--d** Opacified IOL explantation together with the capsular bag. **e**, **f** Iris-claw lens implantation on the posterior surface of the iris.](cop-0004-0151-g01){#F1}

![After the explantation, the Akreos Adapt AO IOL showed diffuse deposits that seem to be inside the optic.](cop-0004-0151-g02){#F2}
